Esperion Therapeutics, which is developing a treatment for elevated levels of low-density lipoprotein cholesterol, raised $70 million by offering 5.0 million shares at $14, within the range of $13 to $15. Esperion Therapeutics plans to list on the NASDAQ under the symbol ESPR. Esperion Therapeutics initially filed confidentially on April 12, 2013. Credit Suisse and Citi acted as joint bookrunners on the deal.
